Sato Pharmaceutical,
Advancing Healthcare Innovation
for a Sustainable Future
As a nation with a steadily declining birthrate and aging population, Japan faces a significant challenge in maintaining its presence on the global stage. We need to foster a society in which everyone can thrive and reach their full potential in this global age of constant change.
The Japanese government’s Basic Policy on Economic and Fiscal Management and Reform 2025 identifies “strengthening drug discovery capabilities and promoting innovation” as a key policy for assuring continued economic growth. It highlights the importance of efforts to expand the healthcare market, strengthen foundations for drug discovery and further switch pharmaceuticals to OTC products, which will promote self-care and self-medication.
In our mainstay healthcare business, we have launched new Switch OTC drugs that used to be available only by prescription, including high-demand medications for rhinitis and gastrointestinal issues. We are working to enhance brand value through efforts that include appointing a new brand ambassador for our flagship brand, YUNKER.
In the pharmaceutical business, we offer highly original products primarily in the field of dermatology, such as antifungal treatments for onychomycosis (nail fungus). To raise awareness of this, we are taking a multifaceted approach that includes TV commercials and online modes of information-sharing. In new drug creation and development, we are actively collaborating with domestic and international business partners and pursuing joint research with universities and research institutions, while enhancing our own research facilities to accelerate the synthesis of new compounds.
In our global business, our six bases in Asia, North America and Europe promote our strategy of developing global brands and conduct marketing tailored to the needs of each region, with a focus on OTC drugs. We are expanding the reach of our pharmaceuticals globally, including our topical onychomycosis treatment, LUCONAC, into Asia, using Singapore as a base, and are developing antifungal agents in North America.
In our CSR pursuits, we continue to work toward the SDGs by fostering an atmosphere that supports self-care and self-medication. Through the OTC Self-Medication Promotion Foundation and our new collaboration with Keio University in establishing a Healthcare Innovation in Pharmacy course, we are developing human resources to contribute to society. We also work to protect the environment, primarily at our production sites.
Guided by a corporate philosophy of promoting healthcare innovation, Sato Pharmaceutical has made steady advances over the years, decade upon decade. We will continue to contribute to consumer health through our healthcare-related businesses centered around OTC drugs and pharmaceuticals as we help to build a sustainable society. I hope that we may draw upon your continued advice and support going forward.
Seiichi Sato
President and CEO
